Not Signed In -
Vascular Headache |
|
|
Clinical Trial: A Study Using Botulinum Toxin Type A as Headache Prophylaxis for Migraine Patients with Frequent Headaches
This study is not yet open for patient recruitment.
Verified by Allergan September 2005
|
Purpose
This is a 60 week study including a double-blind phase followed by an open-label extension phase.
| Condition | Intervention | Phase |
|---|---|---|
| Migraine with frequent headache | Drug: botulinum toxin type A | Phase III |
MedlinePlus consumer health information
Study Type: Interventional
Study Design: Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Safety/Efficacy Study
Further Study Details:
Primary Outcomes: Frequency of headache episodes
Secondary Outcomes: Frequency of headache days; Frequency of acute headache pain medication use
Expected Total Enrollment: 650
Secondary Outcomes: Frequency of headache days; Frequency of acute headache pain medication use
Expected Total Enrollment: 650
Eligibility
Ages Eligible for Study: 18 Years - 65 Years, Genders Eligible for Study: Both
Criteria
Inclusion Criteria: Frequent migraine (>=15 headache days per month);
Exclusion Criteria: Previous use of botulinum toxin of any serotype or immunization to any botulinum toxin serotype
Location and Contact Information
Please refer to this study by ClinicalTrials.gov identifier NCT00156910
Allergan Inc clinicaltrials@allergan.com
More Information
Study ID Numbers: 191622-079
Last Updated: September 10, 2005
Record first received: September 7, 2005
ClinicalTrials.gov Identifier: NCT00156910
Health Authority: United States: Food and Drug Administration
ClinicalTrials.gov processed this record on 2005-09-13
Last Updated: September 10, 2005
Record first received: September 7, 2005
ClinicalTrials.gov Identifier: NCT00156910
Health Authority: United States: Food and Drug Administration
ClinicalTrials.gov processed this record on 2005-09-13
email this page
print this page
bookmark this page
feedback on this page
